CLASS ACTION UPDATE for LICY, OSCR and OKTA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, NY / ACCESSWIRE / May 26, 2022 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

LICY Shareholders Click Here: https://www.zlk.com/pslra-1/li-cycle-holdings-corp-loss-submission-form?prid=27791&wire=1
OSCR Shareholders Click Here: https://www.zlk.com/pslra-1/oscar-health-inc-loss-submission-form?prid=27791&wire=1
OKTA Shareholders Click Here: https://www.zlk.com/pslra-1/okta-inc-loss-submission-form?prid=27791&wire=1

* ADDITIONAL INFORMATION BELOW *

Li-Cycle Holdings Corp. f/k/a Peridot Acquisition Corp. LICY

LICY Lawsuit on behalf of: investors who purchased February 16, 2021 - March 23, 2022
Lead Plaintiff Deadline : June 20, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/li-cycle-holdings-corp-loss-submission-form?prid=27791&wire=1

According to the filed complaint, during the class period, Li-Cycle Holdings Corp. f/k/a Peridot Acquisition Corp. made materially false and/or misleading statements and/or failed to disclose that: (1) Li-Cycle's largest customer, Traxys, is not actually a customer, but merely a broker providing working capital financial to the Company while Traxys tries to sell Li-Cycle's product to end customers; (2) the Company engaged in highly questionable related party transactions; (3) the Company's mark-to-model accounting is vulnerable to abuse and gave a false impression of growth; (4) a significant portion of the Company's reported revenues were derived from simply marking up receivables on products that had not been sold; (5) the Company's gross margins have likely been negative since inception; (6) the Company will require an additional $1 billion of funding to support its planned growth (which is a figure greater than the Company raised via the merger); and (7) as a result, Defendants' public statements were materially false and/or misleading at all relevant times.

Oscar Health, Inc. OSCR

This lawsuit is on behalf of persons and entities that purchased or otherwise acquired Oscar Class A common stock pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company's March 2021 initial public offering.
Lead Plaintiff Deadline : July 11, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/oscar-health-inc-loss-submission-form?prid=27791&wire=1

According to the filed complaint, (1) Oscar was experiencing growing COVID-19 testing and treatment costs; (2) Oscar was experiencing growing net COVID costs; (3) Oscar would be negatively impacted by an unfavorable prior year Risk Adjustment Data Validation result relating to 2019 and 2020; (4) Oscar was on track to be negatively impacted by significant SEP membership growth; and (5) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Okta, Inc. OKTA

OKTA Lawsuit on behalf of: investors who purchased March 5, 2021 - March 22, 2022
Lead Plaintiff Deadline : July 19, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/okta-inc-loss-submission-form?prid=27791&wire=1

According to the filed complaint, during the class period, Okta, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Okta had inadequate cybersecurity controls; (ii) as a result, Okta's systems were vulnerable to data breaches; (iii) Okta ultimately did experience a data breach caused by a hacking group, which potentially affected hundreds of Okta customers; (iv) Okta initially did not disclose and subsequently downplayed the severity of the data breach; (v) all the foregoing, once revealed, was likely to have a material negative impact on Okta's business, financial condition, and reputation; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP